Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model

• Váldodahkkit: Ashit Trivedi (Dahkki), Winnie Sohn (Dahkki), Priyanka Kulkarni (Dahkki), Pegah Jafarinasabian (Dahkki), Hanze Zhang (Dahkki), Marintan Spring (Dahkki), Stephen Flach (Dahkki), Siddique Abbasi (Dahkki), Jan Wahlstrom (Dahkki), Edward Lee (Dahkki), Sandeep Dutta (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2021-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmac...